Sugi Predict

Sugi Predict / Compounds / SCHEMBL127671

SCHEMBL127671

SCHEMBL127671

COC(=O)c1c[c]ccn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 3/20 0.42
▸ ALDH1A1 P00352 4/20 0.38
▸ KDM4E B2RXH2 5/20 0.37
▸ MAPT P10636 2/20 0.37
▸ POLB P06746 1/20 0.37
▸ L3MBTL1 Q9Y468 2/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.35
▸ PKM P14618 1/20 0.35
▸ RAB9A P51151 2/20 0.35
▸ AR P10275 1/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ NFKB1 P19838 1/20 0.35
▸ NFKB2 Q00653 1/20 0.35
▸ RELA Q04206 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ KDM6B O15054 1/20 0.34
▸ KDM5C P41229 1/20 0.34
▸ KDM4C Q9H3R0 1/20 0.34
▸ KDM2A Q9Y2K7 1/20 0.34
▸ KDM3A Q9Y4C1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7085583 0.81 ADORA3 (0.31) —
SCHEMBL129258 0.80 ALDH1A1 (0.37) ALDH1A1MAPTRAB9ANPC1
SCHEMBL132238 0.80 CYP1A2 (0.47) ALDH1A1KDM4EMAPTPOLBNPSR1
SCHEMBL2442016 0.80 HPGDS (0.37) ALDH1A1MAPT
SCHEMBL2878233 0.80 SMN1; SMN2 (0.33) ALDH1A1KDM4EMAPTPKMRAB9A
SCHEMBL1620220 0.78 HPGD (0.40) ALDH1A1KDM4EMAPTPOLBPKM
SCHEMBL8316521 0.78 — —
SCHEMBL126495 0.78 ALDH1A1 (0.42) ALDH1A1KDM4EMAPTPOLBL3MBTL1
SCHEMBL126487 0.75 — —
SCHEMBL128947 0.75 TSHR (0.45) MAPK1ALDH1A1KDM4EMAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140128373-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. 2014-05-08 — — US claimed
CN-103517710-A Compounds and methods for kinase modulation, and indications therefor PLEXXIKON INC 2014-01-15 — — CN claimed
EP-2672967-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR Plexxikon, Inc. (US) 2013-12-18 — — EP claimed
WO-2012109075-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. (US) 2012-08-16 — — WO claimed
CN-1169792-C Substituted vinylpyridine derivatives and medicaments containing them ������ҩ��ʽ���� 2004-10-06 — — CN claimed
EP-0934291-A4 — SMITHKLINE BEECHAM CORP (US) 1999-08-11 — — EP claimed
EP-0934291-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1999-08-11 — — EP claimed
WO-1997016433-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1997-05-09 — — WO claimed
CN-110831926-B Tetrahydronaphtyl urea derivatives 持田制药株式会社 2023-11-21 — — CN disclosed
US-20230277534-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. 2023-09-07 — — US disclosed
CN-115243765-A Biphenyl compounds as SOCE modulators, compositions and uses thereof 皮埃蒙特阿米阿伏伽德罗东方大学 2022-10-25 — — CN disclosed
US-11337976-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON INC. (US) 2022-05-24 — — US disclosed
US-10927079-B2 Intermediate compound of novel tetrahydronaphthyl urea derivative MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2021-02-23 — — US disclosed
US-20200239419-A1 NOVEL TETRAHYDRONAPHTHYL UREA DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2020-07-30 — — US disclosed
WO-1998008830-A1 THIAZOLE DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF PDE-IV BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) 1998-03-05 — — WO disclosed
WO-1998008841-A1 NEW THIAZOLE DERIVATIVES WITH PHOSPHODIESTERASE-INHIBITING EFFECT BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) 1998-03-05 — — WO disclosed
WO-1997016433-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1997-05-09 — — WO disclosed
EP-0247381-B1 5-FLUROROURACIL DERIVATIVES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1993-08-04 — — EP disclosed
US-5047521-A Anticarcinogenic agents OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1991-09-10 — — US disclosed
EP-0247381-A2 5-flurorouracil derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1987-12-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200239419-A1 NOVEL TETRAHYDRONAPHTHYL UREA DERIVATIVE CCNT2, UTS2R, DIMT1 MAPK1 3726/4885ALDH1A1 1467/4885KDM4E 3523/4885
US-10927079-B2 Intermediate compound of novel tetrahydronaphthyl urea derivative CCNT2, DIMT1, QTRT2 MAPK1 3754/4885ALDH1A1 1526/4885KDM4E 3823/4885
US-11337976-B2 Compounds and methods for kinase modulation, and indications therefor MAP3K20, PRKACA, MAP3K13 MAPK1 97/4885ALDH1A1 4369/4885KDM4E 2174/4885
US-20230277534-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR MAP3K20, PRKACA, MAP3K13 MAPK1 97/4885ALDH1A1 4369/4885KDM4E 2174/4885
US-20140128373-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR MAP3K20, PRKACA, MAP3K13 MAPK1 97/4885ALDH1A1 4369/4885KDM4E 2174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.